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Abstract
Introduction: Tuberculosis (TB) is a leading cause of morbidity and mortality in South Africa. Clinical parameters are
important objective outcomes in TB; however they often are not directly correlated with subjective well-being of
the patient, but can be assessed using patient-reported outcome (PRO) measures. Health-related quality of life
(HRQOL) is a specific PRO generally multi-dimensional in nature and includes physical, mental and social health
domains. The inclusion of HRQOL PROs in trials and clinical practice can provide additional information
beyondclinical and microbiological parameters. Furthermore, HRQOL may be associated with medication adherence.
This review focuses on patient-reported HRQOL and its association with medication adherence in TB patients in South
Africa.
Methods: A comprehensive search strategy was developed focusing on the impact of TB on patient-reported
HRQOL,the existence of a conceptual framework of TB-specific HRQOL, determinants of medication adherence
and the association of HRQOL with medication adherence. Data were extracted from all identified articles and
additionaldata extraction was performed by two independent reviewers with special focus on longitudinal studies in
order to understand changes of HRQOL and adherence over time. Research gaps were identified with regard to patient-
reported HRQOL and medication adherence.
Results: A total of 66 articles met the eligibility criteria. Ten HRQOL studies and one adherence study used a longitudinal
design, none of these in South Africa. A variety of different generic and disease-specific HRQOL measures were identified
in the articles. In South Africa four HRQOL and five adherence studies (non-longitudinal) were published. Similar factors
(socio-demographic, socio-economic, disease-related, therapy-related and psycho-social aspects) affect HRQOL and
adherence. Although standard TB treatment improved all health domains, psychological well-being and social
functioning remained impaired in microbiologically cured patients after treatment.
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Conclusion: While evidence of TB impact on HRQOL and medication adherence and their association exists, it is
verylimited for the South African situation. No valid and reliable TB-specific HRQOL measures were identified in this
systematicreview. An assessment of HRQOL in TB patients in South Africa is required as this may assist with
improving current disease management programmes, medication adherence and national treatment guidelines.
Keywords: Health-related quality of life, Medication adherence, Tuberculosis, Patient-reported outcomes, South
Africa
Background
The global burden of tuberculosis (TB) is still a major
public health concern although the United Nation’s Mil-
lenium Development Goals (MDGs) target to reverse TB
incidence by 2015 has been achieved. Around 9.6 million
new TB cases and 1.5 million TB deaths were estimated
to occur in 2014 worldwide [1]. Twenty-two high-burden
countries defined by the World Health Organization
(WHO) account for 80 % of all TB cases. Despite the
availability and affordability of effective TB medication
South Africa has the highest prevalence and incidence
rates (696 and 834 cases per 100,000 population) among
these countries [1] TB is South Africa’s leading cause of
mortality (134 cases per 100,000 population). TB is known
to impact health-related quality of life (HRQOL) [2–4]. Ef-
fective treatment, relapse and the emergence of multi-
drug resistant TB (MDR-TB) are closely related to TB
treatment adherence and consequent HRQOL [5]. The as-
sessment of an association between both, HRQOL and
medication adherence in TB, would provide valuable in-
formation on treatment effectiveness, optimal disease
management and health policy making.
Patient-reported outcomes (PRO’s) provide unique evi-
dence of different aspects of the experience of living with
a disease or condition and how important these aspects
are to patients. In this sense, they go beyond clinical pa-
rameters and respect the integrated nature of health,
ideally encompassing physical, mental and social well-
being. The measurement of HRQOL using PRO’s allows
for a multidimensional understanding of health, an evalu-
ation of disease and treatment impact on the health condi-
tion and the patients’ daily life. It is strongly related to the
World Health Organization’s (WHO’s) definition of health
as “a state of complete physical, mental and social well-
being and not merely the absence of disease or infirmity”
[6]. A comprehensive knowledge of HRQOL in TB pa-
tients can allow for identification of treatment gaps. Ad-
dressing these gaps will lead to improvement of health
care services and disease prevention strategies, and sup-
port health policy making. A number of countries such as
the UK, Germany and Australia rely on PRO data about
medical interventions for pricing, reimbursement and
health policy decision-making about medical interventions.
South Africa is becoming increasingly aware of the import-
ance of such outcome evaluations and has released its first
guidance on pharmacoeconomic submissions in February
2013 [7]. The aim of this systematic review was to under-
stand HRQOL and medication adherence during TB treat-
ment and how both concepts are associated based on
international literature. Longitudinal studies were of par-
ticular interest to understand changes in HRQOL and ad-
herence during the course of TB treatment. The focus of
this research lies on active pulmonary TB and not on latent
TB (LTBI), MDR-TB, XDR-TB, TB in children or TB with
HIV co-infection, as these types of TB show different
HRQOL outcomes [8]. As South Africa suffers from a
major TB burden, we put a specific focus on HRQOL and
adherence to TB treatment in the South African health
setting.
Review
Methods
Search strategy for identification and selection of relevant
studies
A systematic literature search has been performed in
PubMed, EMBASE and PsychINFO, with the last search
conducted on 22 February 2015. Search terms applied in-
cluded tuberculosis, health related quality of life, HRQOL,
quality of life, South Africa, patient-reported outcomes, out-
come assessment, life quality, well-being, adherence, non-
adherence and compliance; different combinations were
used (Table 1 in the Additional file 1). Each search term
combination resulted in different initial hits which were
screened by title and abstract. Articles were excluded if
they were not related to the pre-defined search terms or
were published in a language other than English. Dupli-
cates were removed. The full texts of all remaining articles
were reviewed. References cited by the identified publica-
tions were additionally scanned for relevant studies. Data
on TB and adherence was additionally taken from the
WHO and the Department of Health of the Republic of
South Africa. Data from articles with a longitudinal study
design were separately extracted and included when psy-
chometric validity and reliability were reported for
HRQOL or adherence measures, when changes in HRQOL
during TB treatment including at least baseline and end of
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treatment were reported, and when the study population
consisted of new TB cases treated as outpatients.
Data quality and data extraction
Data from all identified articles was extracted and
structured according to physical, mental and social
health aspects of HRQOL; data on medication adher-
ence was summarized. Research on HRQOL and medi-
cation adherence in South Africa was described
separately. In addition, studies with a longitudinal de-
sign were subject to a separate; subsequent data extrac-
tion performed by two independent reviewers. This
additional extraction covered the PICOS elements (P =
population, I = intervention, C = comparator or control,
O = outcome, S = study design), with additional items
covering major research topic, study objective, study
setting, sample size, PRO measure applied and meas-
urement time points. Prior to data extraction, all longi-
tudinal studies underwent quality assessment. As
longitudinal studies were observational in nature, qual-
ity of reporting was evaluated using the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) statement [2]. A STROBE quality checklist
with 8 items was applied, with scores ranging from 0
(no quality) to 16 (best quality) [2].
Results
Our literature search in PubMed, EMBASE and Psy-
chINFO yielded 988 initial hits. After screening by title
and abstract and after removal of duplicates, 61 articles
remained. An addition of three WHO reports, two guide-
lines from the South Africa’s Department of Health and
one article identified by hand search of citations resulted
in 67 eligible articles for this systematic review. One article
was excluded, yielding 66 eligible full-text articles (Fig. 1).
A detailed description of the literature search is available
in the Additional file 1: Figure 1-4. The 66 articles com-
prised 22 cross-sectional studies, 17 longitudinal studies, 7
(systematic) reviews, 8 qualitative studies and 12 articles
including editorials, comments and letters (Table 2 in the
Additional file 1). Nine studies were performed in South
Africa (four HRQOL and five medication adherence stud-
ies; Table 4 in the Additional file 1). All final 66 articles
underwent extraction of information about HRQOL and
adherence in TB. The 17 identified longitudinal studies
were potentially eligible for separate data extraction; 11 of
them actually met the eligibility criteria for separate data
extraction, while 6 studies were excluded as eligibility cri-
teria were not met (Table 3 in the Additional file 1). Appli-
cation of the STROBE quality of reporting checklist to the
11 longitudinal studies resulted in a median score of 7 for
HRQOL studies, with scores ranging from 5 to 11 out of
Fig. 1 Flow diagram of literature search in the databases PubMed, EMBASE and PsychINFO; additional articles were obtained from World Health
Organization and Department of Health Republic of South Africa
Kastien-Hilka et al. Health and Quality of Life Outcomes  (2016) 14:42 Page 3 of 13
16 (the greater the score the higher the quality of report-
ing). The adherence study had a score of 10 (Table 3 in
the Additional file 1).
TB impact on HRQOL
The systematic review found that TB has a negative im-
pact on patients’ HRQOL and overall wellbeing [3, 9–13].
Factors associated with HRQOL in TB included socio-
demographic (age, gender) and socio-economic (income,
education, housing, social security) factors, disease-related
(symptoms) and therapy-related (side effects, adverse
events) factors and psycho-social aspects (isolation and
stigmatization, psycho-social burden) [2, 4, 9, 10, 13–30].
There was some evidence to suggest that amongst TB pa-
tients, psycho-social burden may have a greater impact
than clinical symptoms [3, 13]. The results of this litera-
ture review identified that TB treatment resulted in a sig-
nificant improvement in HRQOL, especially in physical
and psychological dimensions [2, 4, 10, 17–19, 22, 23, 27,
29]. The improvement in HRQOL was greatest during the
first 2–3 months (intensive treatment phase) [2, 23]. The
results also revealed that although a patient was defined as
microbiologically cured following successful treatment,
morbidity still existed due to anatomic and functional
changes of the lung at treatment completion [17, 31–33].
Specifically, a state of chronic morbidity continued which
resulted in health quality loss that differed for developing
countries with regard to their socio-demographic and
-economic situation [34–36]. It was also noted that the as-
sessment of HRQOL has currently not been integrated
into the WHO guidelines for TB treatment, national
guidelines or TB control programmes [37]. An important
consideration from the results of the review was that
patient-reported HRQOL outcomes may differ after the
end of treatment depending on the HRQOL measures ap-
plied as different measures may measure different con-
cepts [4, 10, 19, 38–40].
TB impact on physical health
TB impacts physical health, resulting in impaired phys-
ical functioning, development of fatigue, adverse events
of treatment and increased use of health care services.
Major physical impairment was reported through som-
atic symptoms and other TB related physiological out-
comes [3, 4, 13, 18]. The impairment in HRQOL was
worse in patients with HIV co-infection [15]. Impaired
physical functioning was closely related to the develop-
ment of fatigue [3, 13]. The literature revealed that fa-
tigue was triggered through sleep disturbances, coughing
and malnutrition and TB medication [13]. Drug-based
treatment of TB impacted HRQOL in two ways. Whilst
the TB treatment resulted in a significant improvement
in HRQOL [2, 4, 10, 17–19, 22, 29], the drugs taken
often resulted in adverse drug reactions which negatively
affected HRQOL [13]. The greatest physical impact on
HRQOL was caused by the large quantity of pills and
the treatment duration, and a reduction in both was ex-
pected to improve HRQOL [13]. Health care services
may have a negative effect on HRQOL through the rela-
tionship between healthcare worker and patient, espe-
cially due to a lack of knowledge and misunderstanding
about TB. This relationship was not only important for
the degree of compliance with the current TB treatment
guidelines, but also comprised emotional support and
disease-related information through nurses [16, 41].
TB impact on mental health
The impact of TB on mental health related to psycho-
logical, emotional and spiritual wellbeing and patients
perceptionof their health. Psychological distress was com-
monly reported among TB patients [42, 43], with depres-
sion and anxiety being the most frequently reported mental
disorders [42, 44], especially in TB patients diagnosed with
post-traumatic stress disorder (PTSD) [45]. Besides depres-
sion and anxiety, feelings of anger were also reported [13].
Psychiatric co-morbidity may increase the distress of phys-
ical illness, prolong recovery time and may also lead to poor
treatment compliance [43]. Psychological distress may be
caused by social stigmatization followed by social isolation
during TB treatment and impacted financial situation
[13, 42, 46]. Mental disorder in TB patients was associated
with socio-demographic and economic factors and in HIV
co-infected TB patients also with stigmatization and per-
ceived health status [15, 42]; a misconception about TB in-
cluding fear of dying, disease transmission, disease
symptoms and treatment leads to lower cure and survival
rates as the patient may act according to this misconception
[13, 16]. Prevalence rates of depression and mental disor-
ders among TB patients in low income countries ranged
between 46 and 80 % [42, 44]. About 20 % of non-adherent
TB patients in Pakistan reported depression and anxiety
after treatment completion and developed a multi-drug re-
sistance [44]. TB can also have an impact on caregivers. In
Malaysia caregivers reported poor mental health and an in-
creased risk of depression [47]. TB may affect spiritual well-
being. Patients in the USA experienced TB as a wake-up
call which changed their lifestyle in a positive way. These
patients stopped drinking alcohol, adopted a healthier life-
style and became more concerned about their health [13].
TB impact on social health
Diagnosis and treatment of TB can have an impact on so-
cial health including reduced social functioning and an in-
creased financial burden as a result of stigmatization [13].
Social functioning often comprises roles at the workplace,
in the community and within the family [3, 13]. The infec-
tious nature of TB can lead to a stigma and disruption of
social interaction with others, resulting in social isolation
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[26]. TB-related stigmatization was often associated with
stigma of HIV and AIDS [43, 48]. Many TB patients were
unable to work due to the travel distance between a health
clinic they get the treatment from and workplace, but also
due to the disease induced worsening of their physical
condition [3, 13, 16]. This may affect the financial and
economic situation of TB patients in terms of limited
work capacity or inability to work which could lead to a
decrease in income or even a total loss of income [13, 16].
Saving travel expenses to reduce the financial burden
maylead to medication non-adherence [3]. Some studies
indicated that a better financial empowerment could im-
prove TB-related depression, medication adherence and
HRQOL [42, 46]. Often family members needed to get in-
volved as caregivers leading to a loss of income by either
through reducing their own work [3] or by providing finan-
cial support to the patients [13]. TB induced fatigue may
impair the sexual function of the patient [13].
South African studies on HRQOL in TB
In this review four studies which evaluated HRQOL in
TB patients in South Africa were identified. All of them
applied a cross-sectional design and had a strong focus
on psychological distress and mental health [22, 42, 43, 45]
(Table 3 in the Additional file 1). The evidence shows that
TB impacted physical functioning and mental health
domains of HRQOL. Mental disorders and psychological
distress were present in TB and TB/HIV co-infected pa-
tients [42]. Depression was most prevalent (64 %), followed
by PTSD (30 %), feeling of helplessness and a lack of social
support [43, 45]. It was proposed that the integration of
screening, treatment and mental health care services for
TB patients [42, 45] would improve the quality of health
and health outcomes of TB and HIV co-infected patients
in South Africa [22].
Adherence to treatment
Medication adherence is a complex, multi-dimensional,
dynamic phenomenon comprising patient behavior with
regard to the prescribed interval, dose and dosing regi-
men as well as appropriateness of how the medication is
taken [49, 50]. In the absence of drug resistance, TB is a
curable disease with a six month treatment of antibiotics
[51]. Medication adherence is a key factor for treatment
success [52], and might have a greater impact on a pop-
ulation’s health than any improvement in specific med-
ical treatments [53]. Adherence during the intensive
treatment phase (first two months) increases the chance
for cure in newly diagnosed patients [51]. In contrast,
non-adherence leads to spread of free TB bacteria in the
community; this may impact the patient by resulting in
disability, drug resistance, relapse and risk of death and the
community by increased health costs [51, 52, 54, 55].
There is no gold standard on how to measure medication
adherence. Conventional ways of adherence control in TB
include pill counting and Directly Observed Treatment
(DOT); under DOT medication intake is directly observed
and thereby it is a surveillance tool to control adherence. A
Cochrane systematic review [56] compared DOT with self-
supervised TB medication treatment. While DOT is an ob-
jective mechanism to control adherence, self-supervised
treatment depends on the subjective adherence behavior of
the patient. The Cochrane review showed no differences in
adherence between the two approaches; further clinic
based DOT and community based DOT showed no differ-
ences. DOT is a key element of DOTS (Directly Observed
Therapy, Short course), a TB management programme
fromWHO that comprises five elements: government con-
trol, detection, medication supply, supervised treatment
and monitoring of TB [56, 57]. Although DOTS is com-
monly practiced, the cure rates in some countries are still
low due to poor adherence [57]. A number of studies
[14, 40, 41, 43, 47, 48, 50, 54–57] identified qualitatively
different factors affecting adherence based on behavioral
sciences: therapy-related (adverse events), condition-
related (TB symptoms, psychological stress and depres-
sion), socio-economic and demography-related (gender,
age, food access,education, marital status), health system
related (inadequate relationship between health care pro-
vider and patient, poor health infrastructure) and patient-
related (forgetfulness, drug abuse). Adherence may also be
influenced by family pressure, insufficient social support, a
fear of disclosure, migration within the country or to
neighboring countries. Health beliefs of the patient play a
major role in adherence [54, 55] and may impact adher-
ence positively [44, 55, 58–60] or negatively [54, 57]. Ma-
terial incentives and enablers promote and assist
adherence to TB treatment through higher clinic attend-
ance [60, 61]. Material incentives include cash or non-cash
vouchers and promoteadherence in form of a positive re-
ward of the patient’s adherence behavior. Enablers as-
sist adherence by directly acting to overcome financial
barriers to treatment such as transport vouchers or
food; it is unknown whether incentives and enablers
will improve adherence in the long-term [61].
South African studies on adherence
Four studies assessed adherence to TB medication in
South Africa: two cross-sectional studies [62, 63] and two
qualitative studies [54, 57] (Table 3 in Additional file 1).
These studies indicated that TB patients were more adher-
ent during the first two months of treatment (intensive
phase) when symptoms were more present. Patients be-
lieved that they could be cured through effective treat-
ment and through a good health alliance with their health
care professional [54, 57]. A qualitative study by Naidoo
et al. [57] identified a number of themes in a DOTS envir-
onment in South Africa which affect adherence behavior.
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Non-adherence was related to poverty, HIV co-infection,
stigmatization, an unsupportive social and work environ-
ment, and feelings of helplessness and hopelessness [57].
Although the psycho-social burden in TB was higher than
in HIV patients, adherence to both treatments was com-
parable and the psycho-social burden did not impact
adherence [63]. Non-adherence was mainly affected by
limited food access, a lack of public transport to clinics,
the cost of transport and through social stigmatization
[54, 57]. The two cross-sectional studies observed adher-
ence by economic incentives and by patient reported out-
comes. One study revealed that material incentives such
as monthly vouchers of US$15 given during treatment did
improve treatment completion; 35 % of patients receiving
no material incentives completed treatment while 43 % of
patients receiving vouchers did complete the treatment
[62]. However the study was affected by a low fidelity
tothe delivery of vouchers in public health clinics and
further research into this is required. The other study
compared medication adherence between TB and HIV
patients by applying the patient-reported Morisky
Medication Adherence Scale and by counting missed
appointments [63]. On average TB patients missed
1.85 days of treatment and had a good self-reported ad-
herence in this study.
The association between HRQOL and adherence during TB
Our systematic review identified one study which ad-
dressed the association between well-being and adherence
in TB. This study was a meta-analysis of 44 qualitative
studies including 8 studies from South Africa about adher-
ence to TB treatment by Munro et al. [5]. The systematic
review indicated two underlying mechanisms for the asso-
ciation between well-being and adherence. The first mech-
anism related to TB patients prematurely stopping their
treatment because they felt better. The reason was that
patients perceived the improvement in well-being as a
cure of TB. On the other hand, the second observed
mechanism referred to patients stopping treatment when
they experienced no improvement or a worsening in their
health status and well-being [5, 53].
HRQOL and adherence in longitudinal studies
Ten observational studies with a longitudinal design evalu-
ating HRQOL in new smear-positive TB cases receiving
TB treatment were eligible for separate data extraction as
shown in Table 1 [10, 17, 19, 26, 28, 29, 39, 64–66]. Three
studies took place in India [10, 19, 26], two in Indonesia
[17, 66], and one each in Canada, China, Malaysia, the UK
and Western Iran [28, 29, 39, 64, 65]. Studies evaluated
HRQOL at diagnosis or before treatment, after 4 weeks of
treatment, at switch from intensive to continuous phase at
two months following treatment initiation, after three
months and at the end of treatment after six month. Only
one study did not include HRQOL data for the end of
treatment time point [39]. Sample size varied from 30 [19]
to 1034 [10] with a mean sample size of 206. Seven differ-
ent HRQOL measures indentified in this review; three
were generic (SF-36, WHOQOL-BREF, EQ-5D), three
were dimension-specific measures, either for depression
(BDI and Center for Epidemiologic Studies Depression
Scale), or for anxiety (State-Trait Anxiety Short Form), and
one was respiratory-specific (St. George’s Respiratory
Questionnaire (SGRQ)). Independent from HRQOL meas-
ure and health setting, all studies reported impaired
HRQOL before TB treatment and an improvement in
HRQOL due to TB treatment. However, it was noted that
residual impairment in HRQOL remained in some patients
after successful treatment [10, 26, 28, 64]. Variables which
were shown to predict lower HRQOL prior to treatment
initiation included low socio-economic status and depres-
sion [39, 64]. It was also identified from the studies in-
cluded in the review that HRQOL is most affected in
physical and psychological or mental domains [29, 65].
The greatest improvement observed in HRQOL due to
treatment was in the physical domain [26, 39].
In terms of adherence, there was only one study identi-
fied that followed a longitudinal approach [51]. This study
assessed medication adherence by counting missing days
from patient medical record cards. About 35 % of patients
were non-adherent to TB treatment, with the majority
missing less than 15 days of treatment. No longitudinal
study addressed the association between HRQOL and ad-
herence in TB.
Discussion
This systematic review addressed the issues relevant to
understand the impact of TB on HRQOL and medication
adherence from a global perspective and specifically for
South Africa using an integrative health approach. TB im-
pacts the physical, emotional, psychological, social and eco-
nomic dimensions of HRQOL, and residual impairment
may be still present after treatment. We identified thirty-
six studies evaluating HRQOL in TB of which twenty-one
studies took place in WHO’s high-burden TB countries.
Atif et al. [67] reported that most HRQOL studies in TB so
far applied a cross-sectional design and our systematic re-
view confirms this finding. Thirteen studies across high-
burden countries had a cross-sectional design while only
eight studies evaluated longitudinal changes (Table 2). To
date, very few studies have followed changes in HRQOL
longitudinally over time in TB patient populations. No lon-
gitudinal study has been conducted in South Africa even
though South Africa has the highest prevalence and inci-
dence among the 22 high-burden TB countries worldwide.
Our understanding of the long-term impact of TB on
HRQOL, covering the time of treatment and after treat-
ment, is limited. There is a need for further research
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Table 1 Data Extraction of longitudinal studies evaluating HRQOL and adherence in TB
Reference Study Objective Study Setting/
Sample Size
Population Comparator
Group
HRQOL Measure Application time point
of HRQOL Measure
Overall Outcome in
HRQOL
Outcomes in HRQOL Domains
Aggarwal et al.
2013 [10]
To quantify
impairment in
HRQOL and to
evaluate the utility
IndiaN = 1034 Newly diagnosed
PTB patients
None WHOQOL-BREFHindi
version
1st time point: within
2 weeks of initiating
intensive phase 2nd
time point: within
2 weeks of switching
to continuation phase
3rd time point: within
2 weeks of stopping
treatment
Impaired HRQOL
improves significantly
with anti-tuberculosis
treatment. Residual
impairment is noticed
in some patients at the
end of treatment
Patients in urban areas and those
with higher socioeconomic status
(SES) have higher domain scores
and better HRQOL. The WHOQOL-
BREF physical and psychological
domain scores are significantly
lower and more affected than
other domains.
Atif et al. 2014
[64]
To evaluate the
impact of TB
treatment on
HRQOL
Malaysian = 216 New smear
positive PTB
patients; no HIV
co-infection
None SF-36 v2 Tamil, Malay
and Mandarin version
1st time point: start of
treatment 2nd time
point: end of
intensive phase 3rd
time point: end of
treatment
Impaired HRQOL
improves significantly
with anti-tuberculosis
treatment. Scores inthe
physical and mental
health components
were still impaired after
end of treatment
Health domains improve between
baseline and end of the intensive
phase, and end of treatment,
except for bodily pain and vitality.
At the start of treatment, 67.1 % of
patients are at risk of depression,
compared to 35 % at end of
intensive phase and 23.5 % at end
of treatment. Patients aged
<45 years and/or non-smokers
have a better mean physical
component summary (PCS)score.
Lower and affected mental health
is related to smoking, low income
and presence of more than three
TB symptoms.
Balgude et al.
2012 [19]
To assess the
impact of TB and
treatment on
HRQOL
Indian = 60, (30
patients and 30
controls)
Newly diagnosed
smear positive TB
patients
Healthy
control from
the general
population
WHOQOL-BREF plus
2 items examined
separately
1st time point:
baseline 2nd time
point: after 2 months
3rd time point: after
4 months
At baseline, HRQOL is
significantly affected
with physical and
psychological domains
most affected. All
domains improve after
2 and 4 month
treatment.
Mean scores of patients’ physical
and psychological domains are
lower than controls at all 3 time
points of assessment. There is
significant improvement in the
scores at 2 & 4 months of
treatment. The mean scores of
patients’ environmental and
social domains are lower than
control at baseline, but improve
at 4 months of treatment and
are comparable to control
Chamla 2004
[29]
To assess impact
of TB and
treatment on
HRQOL
Chinan = 205,
(102 patients
and 103
controls
TB patients General
population
without TB
SF-36Chinese version 1st time point: before
treatment 2nd time
point: after 2 months
3rd time point: end of
treatment.
HRQOL is impaired at
baseline with physical
scales most affected
and improves due to
treatment.
Treatment improves all domains;
at end of treatment physical
functioning, role-emotional, bodily
pain, social functioning and
general health are not different
from control. Physical scales are
more commonly affected than
mental health scales.
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Table 1 Data Extraction of longitudinal studies evaluating HRQOL and adherence in TB (Continued)
Dhuria et al.
2009 [26]
To assess impact
of TB and
treatment on
HRQOL
Indian = 180,
(n = 90 patients
and 90
controls)
TB patients General
population
matching for
age, gender
and
socioeconomic
status
WHOQOL-BREFHindi
version
1st time point:
baseline 2nd time
point: 3 months 3rd
time point: end of
treatment.
TB patients have an
impaired HRQOL with
significant
improvement in all
domains except social
domain after treatment.
The highest improvement is in
physical domain, followed by
psychological domain. The mean
score of overall HRQOL and
physical domain at completion of
treatment is better in females
than males. Males score better in
psychological, social and
environmental domains. After
end of treatment HRQOL is still
affected in physical domains
compared to healthy controls.
Kruijshaar
et al. 2010 [39]
To assess the
impact of TB and
its treatment on
patients’ health
status
UKn = 61 TB patients None SF-36 v2UK
versionEQ-5DSTAI-6
CES-D
1st time point:
diagnosis 2nd time
point: 2 months
Impaired HRQOL
improves already after
2 month treatment, but
is still below the UK
norm score
SF-36 v2 scores improve
significantly except for physical
functioning, general health
perceptions and physical summary
score. Vitality, mental health and
mental health summary scores are
comparable to the UK norm.
EQ-5D: pain/discomfort andpro-
blems with self-care improvewhile
a borderline decrease is seen for
mobility, except for self-care. De-
pression and anxiety improveddue
to treatment (CES-D andSTAI-6
scores). 51 % report economic
burden due to TB.
Maguire et al.
2009 [66]
To quantify the
impact of TB
HRQOL
Indonesia
n = 115
smear positive
PTB patients
None SGRQ 1st time point:
baseline 2nd time
point: 2 months 3rd
time point: 6 months
Impaired HRQOL
improves with
treatment at 2 and
6 months
Although HRQOL improves due
to treatment 24.6 % of patients
still have significant lung function
impairment after at end of
treatment
Mamani et al.
2014 [65]
To assess the QOL
among TB
patients
Irann = 184 (64
patients and
120 controls)
Pulmonary and
extrapulmonary
TB patients
Healthy
control from
general
population
SF-36Persian version 1st time point:
baseline 2nd time
point: 2 months 3rd
time point: 6 months
Impaired HRQOL
improves due to
treatment compared to
controls
All domains of SF-36 are
significantly impaired and
improve after 2 month treat
ment; improvement between
two and six months is not sig
nificant. Physical functioning
and energy are most affected.
Marra et al.
2008 [28]
To identify areas
of HRQOL affected
by latent and
active TB;
treatment impact
on HRQOL
Canadan = 206
(104 active TB
and 102 latent
TB)
Active and latent
TB patients (LTBI)
LTBI defined
as a positive
TST result
without
radiographic
or clinical
evidence of
active TB
SF-36 v2BDI 1st time point:
baseline 2nd time
point: 3 months 3rd
time point: 6 months
At baseline HRQOL is
more affected in active
than latent TB patients.
Treatment improves
HRQOL in active but
not in latent TB.
Patients with active TB
have still impaired
HRQOL after treatment
All domains of SF-36 improve over
treatment in active and latent TB
except bodily pain inactive and
except social functioning and
vitality in latent TB.BDI showsno
improvement in LTBI
participants, but significant im
provement for those with active TB.
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Table 1 Data Extraction of longitudinal studies evaluating HRQOL and adherence in TB (Continued)
completion compared
to US norms.
Ralph et al.
2013 [17]
To investigate
morbidity over TB
treatment period
Indonesia
n = 240, (200
patients and 40
controls)
smear positive TB Healthy
control from
the general
population
SGRQIndonesian
version
1st time point:
baseline 2nd time
point: 4 weeks 3rd
time point: 8 weeks
4th point time:
24 weeks
Impaired HRQOL
improved over
treatment time.
After treatment 27 % of TB
patients have moderate to severe
pulmonary function impairment.
HIV -positive status was
significantly associated with
worse HRQOL
Reference Study Objective Study Setting Population Comparator
Group
Adherence Measure Application time point
of Adherence
Measure
Overall Outcome in
Adherence
Specific Outcome in Adherence
Chirwa et al.
2013 [51]
To estimate cure
rates, and their
association with
adherence to TB
treatment
Malawin = 524 TB patients None Retrospective
counting of missing
days during
treatment
Retrospective review
of records
Adherence to TB
treatment had a
significant effect on
cure of TB
Overall, 35.1 % of patients did
not fully adhere to TB treatment.
Of these, 86.4 % missed < 15 days
and 23.4 % missed at least 1 day
of treatment Overall, 92.7 % of
patients were cured from TB and
33.7 % of these missed at least
1 day of treatment. Patients who
missed <15 days and 15 to
29 days of treatment were less
likely to be cured compared with
those who fully adhered.
Table 1: data extraction from 11 longitudinal studies evaluating HRQOL (10 studies) and adherence (1 study)
SF-36 short form 36, EQ-5D EuroQol 5 dimensions, SGRQ St. George’s respiratory questionnaire, WHOQOL-BREF World Health Organization Quality of Life Short Form, BDI Beck’s depression index, STAI-6 state-trait anxiety
short-form, CES-D Center for Epidemiologic Studies Depression Scale
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assessing changes in HRQOL longitudinally, specifically in
high-burden countries like South Africa. Most studies on
medication adherence during TB treatment employed a
qualitative approach observing psychometric aspects of ad-
herence. One systematic review of qualitative studies re-
ported an association between HRQOL and adherence TB
[5]. We found that similar factors affect HRQOL and ad-
herence including TB therapy, health condition, socio-
economic and demographic factors as well as quality of
health care services. Studying the association between
HRQOLand medication adherence during TB treatment
will allow for a better understanding of how treatment
effectiveness can be improved and care for TB patients
optimised.
The studies included in this systematic review revealed
similar HRQOL outcomes with a number of different
measures, but a TB-specific measure is lacking. Al-
though two studies reported developing TB-specific
measures, FACIT-TB in Iraq [59] and DR-12 in India
[68], neither provides adequate evidence for validity or
reliability. Measures applied during longitudinal HRQOL
studies were generic (SF-36, WHOQOL-BREF, EQ-5D)
and dimension-specific measures, either for depression
(BDI and Center for Epidemiologic Studies Depression
Scale) or for anxiety (State-Trait Anxiety Short Form),
one measure was specific for respiratory diseases
(SGRQ). All measures reported similar HRQOL out-
comes for TB and confirmed that physical health do-
mains were more affected than mental health domains.
All health domains for each measure improved during
TB treatment. However, physical impairment was still
present after treatment. The measures only capture parts
of the health domains relevant to TB or may not be sen-
sitive enough to observe the actual impact of TB on
HRQOL. This implies the need for a TB-specific PRO
measure which captures all relevant health domains and
health aspects of TB including the physical, psycho-
logical and social domains. Such a measure will need to
consider socio-demographic and cultural differences be-
tween patients with TB, taking into account the stigma
of HIV and how the social standing of the patient within
his or her community is affected. The development of
such a specific measure will also allow a deeper under-
standing of MDR-TB, TB/HIV co-infection and extrapul-
monary TB. Future studies should also include the
identification of minimal clinically important difference
(MCID), i.e. the smallest difference in a domain which
patients perceive as an improvement or a worsening;
This is unknown for TB patients and will allow under-
standing meaningful changes in HRQOL.
Current evidence regarding the association between
HRQOL and adherence in TB is lacking globally. Future
research about the association between HRQOL and ad-
herence in TB specific will help to optimize existing treat-
ment programs, understand the limitations in TB control
and targeted interventions and improving the health sta-
tus of high-burden TB populations. The WHO’s End TB
Strategy targets a TB free world by 2035. One of the three
Table 2 Eligible Studies included in Data Extraction
WHO high-burden country Total Number of HRQOL studies Cross-sectional Design Longitudinal Design
China 2 [29, 69] 1 1
India 6 [10, 12, 19, 26, 33, 70] 1 5
Indonesia 2 [17, 66] 2
Nigeria 2 [14, 46] 2
Pakistan 1 [55] 1
Philippines 1 [9] 1
South Africa 6 [22, 42, 43, 45, 59, 63] 6
Uganda 1 [11] 1
Other countries Total Number of HRQOL studies Cross-sectional Design Longitudinal Design
Canada 3 [27, 30, 40] 2 1
Iraq 1 [58] 1
Malaysia 4 [18, 47, 64, 67] 3 1
Taiwan 1 [20] 1
Thailand 1 [21] 1
UK 1 [39] 1
USA 2 [31, 36] 2
Western Iran 1 [65] 1
Yemen 1 [23] 1
Table 2: Representation of eligible studies included in the systematic review and listed according to their WHO high-burden country status
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strategic pillars to reach this goal focuses on integrated,
patient-centred TB care and prevention. HRQOL assess-
ment allows an integrative understanding of TB from a
patient perspective. Resulting knowledge supports an un-
derstanding of TB-related physical, mental and social
needs and addresses diverse barriers. This patient-centred
approach may support quality assessment and rationale
use of medicines, which fall under the pillars of the End
TB Strategy.
This systematic review had several strength and limita-
tions. It combined qualitative and quantitative research on
HRQOL and adherence and this mixed method may be
viewed as strength as it ensures capturing all relevant in-
formation on the topic. The methodological quality of the
eligible studies varied and might have an effect on the re-
ported outcomes. We only applied the STROBE State-
ment for quality reporting to longitudinal studies; we
observed a moderate reporting quality with a median of 7
out of 16 points, indicating that the quality of the articles
included in this review were fairly poor. This might affect
the reported information. Most studies applied different
PRO measures at differing time points during treatment
at different study sites, making any general conclusions re-
garding the impact of TB on HRQOL difficult. Studies
had an observational nature rather than a controlled trial
design as mostly applied in systematic reviews; however,
observational studies might be more reliable as they ob-
serve patients in real life rather than under controlled
ideal conditions. Publication bias may be present in this
systematic review although our findings were consistent
across different settings; we selected peer-reviewed litera-
ture from three different databases and included grey lit-
erature to control for publication bias. We did not include
unpublished information and studies published in a differ-
ent language than English.
Conclusions
The relevance and importance of HRQOL assessments
is growing and HRQOL has become an important tool
for the understanding of health outcomes adopting a
patient-centred approach to care and treatment. Further
research is required in a country-specific context to con-
tribute to efficient decision making with regard to TB
related strategies; product approval, pricing and reim-
bursement as well as health policy making; A number of
new anti-TB drugs, vaccines and diagnostics have re-
cently achieved marketing approval or are in late clinical
development.Assessment of longitudinal changes in
HRQOL and its association to medication adherence in TB
in a high TB burden country such as South Africa are not
yet available. Such data would support the identification of
sustainable health innovations in TB by providing informa-
tion on benefits and gaps in current treatment strategies
tailored for a specific patient population. This will be useful
to determine the value of new products and to perform ap-
propriate cost-effectiveness analyses to optimize the alloca-
tion of societal resources specifically for South Africa. This
is of high relevance as a number of new TB drugs, vaccines
and diagnostics have recently achieved marketing approval
or are in late clinical development. A longitudinal study
assessing HRQOL and medication adherence in active
TBin South Africa applying valid and reliable measures
that capture all relevant aspects of TB would be neces-
sary to assess the achievement of the WHO’s End TB
Strategy pillars.
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